Treatment
Infliximab clinical trials
We’re tracking 36 recruiting studies that include Infliximab, each written for real people, not researchers, below.
Recruiting studies
- NCT06051253RecruitingPhase 4
Personalized infliximab dosing for active Crohn's fistulas
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
SeoulAges 19–80 - NCT06064864Recruiting
Switching Infliximab from IV to Subcutaneous for Crohn's
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
SeoulAges 18–100 - NCT05180994RecruitingPhase 1/Phase 2
Infliximab eye drops after first corneal transplant
This trial tests infliximab—given as eye drops—after a first corneal transplant to see if it can improve healing and eye outcomes. It may help people at risk of inflammation after surgery, but it also requires careful screening for infection and medication safety.
Montreal, QuebecAges 18–80 - NCT05043870RecruitingPhase 4
Testing medicines that calm the immune system in kids with Crohn’s
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
Shanghai, Shanghai MunicipalityAges 6–18 - NCT03684278RecruitingPhase 2
Infliximab for new acute pancreatitis patients in the first 36 hours
This trial tests infliximab (an anti-inflammatory medicine) versus placebo to see if it improves outcomes in adults with newly diagnosed acute pancreatitis. It is designed for treatment to start within 36 hours of hospital admission.
Aberdeen, AberdeenshireAges 18–85 - NCT05947669RecruitingPhase 3
Infliximab for diarrhea or colitis from immune cancer therapy
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
AalborgAges 18 years+ - NCT04999228RecruitingPhase 4
Top-down versus step-up treatment for pediatric ulcerative colitis
This trial compares two treatment approaches for children newly diagnosed with ulcerative colitis: starting with stronger medicines right away versus beginning simpler and stepping up if needed. It may help your child learn which strategy controls symptoms better with fewer flare-ups.
Shanghai, Shanghai MunicipalityAges 6–18 - NCT06113913RecruitingPhase 4
Switching from IV to under-the-skin infliximab after dose increase
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
Ghent, Oost-VlaanderenAges 18 years+ - NCT07683975RecruitingPhase 4
Infliximab for kidney injury caused by immunotherapy
This study tests whether infliximab can treat kidney damage caused by immune checkpoint inhibitor cancer therapy. It aims to see if this medication helps patients recover kidney function after injury from their cancer treatment.
Boston, MassachusettsAges 18 years+ - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT06059989RecruitingPhase 3
Testing a new form of infliximab for Crohn's disease
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Amsterdam, North HollandAges 18–80 - NCT07550673RecruitingPhase 4
Upadacitinib vs. Infliximab for Severe Ulcerative Colitis
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Ankang, ShaanxiAges 18–85 - NCT07510191RecruitingPhase 4
Comparing two ways to treat Crohn's disease if TNFi isn't working well
This trial tests if adding a low dose of a newer pill (upadacitinib) to your current TNF inhibitor (TNFi) works better than increasing the dose of your TNFi alone. It is for people with Crohn's disease who have had some improvement on their TNFi but still have active disease.
Guangzhou, GuangdongAges 18–65 - NCT06758024Recruiting
Optimizing infliximab for inflammatory bowel disease
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
SantiagoAges 18–75 - NCT06136546RecruitingPhase 2
Infliximab for depression with cognitive problems
This trial tests if a medicine called infliximab, given through an IV, can help improve thinking and memory problems in people with moderate to severe depression who also have high inflammation levels. It aims to see if lowering inflammation can ease both mood and cognitive symptoms.
Boston, MassachusettsAges 25–50 - NCT06453317RecruitingPhase 2
Comparing UC treatments: infliximab vs ustekinumab vs both
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
LodzAges 18–64 - NCT05906576RecruitingPhase 4
Infliximab monitoring study for children with Crohn’s disease
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
BeijingAges 6–17 - NCT05660746RecruitingPhase 2/Phase 3
Infliximab dose tailored to control Crohn’s inflammation
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Los Angeles, CaliforniaAges 6–22 - NCT02638701RecruitingPhase 1/Phase 2
Infliximab for hard-to-treat brain blood vessel aneurysms
This Phase 1/2 trial tests infliximab, a medicine that calms inflammation, for dolichoectactic aneurysms in the vertebral/basilar brain blood vessels that usually cannot be treated with standard surgery or procedures. The goal is to see if it can improve safety and how the aneurysm behaves over time.
San Francisco, CaliforniaAges 18 years+ - NCT04725422Recruiting
Registry for children with nonbacterial bone inflammation
This study collects medical information (and imaging results) from children and teens with nonbacterial bone inflammation. It may help doctors better understand how this condition looks on scans and how it’s diagnosed, especially to rule out infection or cancer.
Seattle, WashingtonAges Up to 21 years - NCT07776782RecruitingPhase 1
Testing a new drug with infliximab in healthy volunteers
This study tests a new experimental drug called MT-201 when given with an existing medicine (infliximab) to healthy people. It helps doctors learn how the drugs work in the body and whether they are safe.
San Diego, CaliforniaAges 19–55 - NCT07694674Recruiting
Comparing Biologic Drugs to Prevent Crohn's Return After Surgery
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT01706692Recruiting
Study registry for targeted treatments in psoriasis patients
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
AarauAges 18 years+ - NCT07491913Recruiting
Stopping biologic therapy for Takayasu arteritis in stable patients
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
IstanbulAges 18 years+
What Infliximab is being studied for
Conditions with recruiting Infliximab studies.
Common questions
- Are there clinical trials studying Infliximab?
- Yes. Clin2 currently lists 36 recruiting studies that include Infliximab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Infliximab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Infliximab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Infliximab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.